Europe GCSF-Filgastrim Market By Route of Administration (Intravenous, Subcutaneous), By Application (Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic and Autoimmune Disorders and Others), By Country – Global Forecast to 2030

Marketresearch.Biz announces publication of its most recently generated research report titled, “Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market by Route of Administration (Intravenous & Subcutaneous), By Application (Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic and Autoimmune Disorders & Other Applications), and by Country – Global Forecast to 2030”, which offers a holistic view of the Europe granulocyte colony stimulator factor (GCSF-filgastrim) market through systematic segmentation that covers every aspect of the target market. The Europe granulocyte colony stimulator factor (GCSF-filgastrim) market is projected to be US$ 2,251.8 Mn in 2020 to reach US$ 4,371.4 Mn by 2030 at a CAGR of 7.0%.

Granulocyte colony-stimulating factor (GCSF) is a glycoprotein that simulates the bone marrow to produce granulocyte (a type of white blood cell) and stem cells and release them into the bloodstream.  A number of various tissues produce a type of colony stimulator factor, known as cytokine and hormone however, pharmaceutical analogs of this naturally occurring GCSF are filgrastim and lenograstim. Filgrastim is used for treatment of low neutrophil count, which me occur owing to various life risking diseases such as HIV/AIDs, following chemotherapy, or radiation poisoning among others.

Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market Revenue (US$ Mn), 2020–2030.The prophylaxis with G-CSF decreases the occurrence of febrile neutropenia (FN), allowing patients to receive and stay on myelosuppressive chemotherapy. The increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is an important factor that is expected to fuel the revenue growth for the granulocyte-colony stimulating factor market in Europe. Also, the rising prevalence of cancer patients owing to unhealthily lifestyles, consumption of processed food, alcohol, and severe smoking habits is a factor that is expected to further bolster the projected financial growth of this given market over the coming years.

Although the high costs associated with initial treatment of chemotherapy, coupled with the high cost of prophylaxis with G-CSF and stringent regulations of respective national authorities towards approval of biosimilar drugs, and high cost of development of this drug are also certain factors that are expected to hamper the revenue growth of this given market.

Approval of biosimilar drugs such as Grafeel, Colstim, Neukine, and Filcad, which are much cheaper as compared to currently available drugs. These biosimilar drugs are expected to create financial growth opportunities for this given market over the forecast period. Moreover, rapid R&D has been witnessed in recent years for the development of new and effective drugs for GCSF that cost-effective as well, resulting in the increased success rate of clinical trials. This trend is expected to continue and further amplify the projected profit margins for this target market in Europe in the coming years.

Europe Granulocyte Colony Stimulator Factor (GCSF-Filgastrim) Market Attractiveness Analysis by Route of Administration, 2014–2030.

The granulocyte colony stimulator factor (GCSF Filgastrim) market in Europe is segmented country-wise into Germany, UK, France, Russia, Italy, Spain, and Rest of Europe, respectively. Among these aforementioned Country, the markets in the Germany segment are expected to register the majority revenue shares of the granulocyte colony stimulator factor (GCSF filgastrim) market in Europe.

The research report on the Europe granulocyte colony stimulator factor (GCSF-Filgastrim) market includes profiles of some of the major companies such as Novartis AG (Sandoz), Pfizer Inc, Amgen Inc, Teva Pharmaceutical Industries Ltd, Stada Arzneimittel AG, Dr. Reddy's Laboratories Ltd, Intas Pharmaceuticals Ltd, Biocon Ltd, Dong-A Socio Holdings Co., Ltd, BioCad.

Europe Granulocyte Colony Stimulator Factor (GCSF Filgastrim) Market Segmentation Based on Route of Administration, Application, and Region

Based on Route of Administration:

• Intravenous
• Subcutaneous

Based on Application:

• Oncological Diseases
• Blood Disorders
• Growth Hormone Deficiencies
• Chronic and Autoimmune Disorders
• Other Applications

Based on Country:

• Germany
• UK
• France
• Russia
• Italy
• Spain
• Rest of Europe